Benecchi Christopher 4
4 · Sage Therapeutics, Inc. · Filed Feb 15, 2023
Insider Transaction Report
Form 4
Benecchi Christopher
Chief Operating Officer
Transactions
- Award
Stock Option (Right to Buy)
2023-02-13+20,900→ 20,900 totalExercise: $45.28Exp: 2033-02-13→ Common Stock (20,900 underlying)
Footnotes (1)
- [F1]The securities awarded on February 13, 2023 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 5,225 shares of common stock shall vest on the one year anniversary of February 13, 2023, with 15,675 shares vesting in 36 equal monthly installments thereafter.